Tildrakizumab (trade name Ilumya (USA)/Ilumetri (European Union)) is a monoclonal antibody designed for the treatment of immunologically mediated inflammatory disorders. In the United States, it is approved for the treatment of moderate-to-severe plaque psoriasis.
The global Tildrakizumab market was valued at xx million US$ in 2018 and will reach xx million US$ by the end of 2025, growing at a CAGR of xx% during 2019-2025.
This report focuses on Tildrakizumab volume and value at global level, regional level and company level. From a global perspective, this report represents overall Tildrakizumab market size by analyzing historical data and future prospect.
Regionally, this report categorizes the production, apparent consumption, export and import of Tildrakizumab in North America, Europe, China, Japan, Southeast Asia and India.
For each manufacturer covered, this report analyzes their Tildrakizumab manufacturing sites, capacity, production, ex-factory price, revenue and market share in global market.
The following manufacturers are covered:
Segment by Regions
Segment by Type
Prefilled 100 mg/mL solution
Segment by Application